Log In
Print
BCIQ
Print
Print this Print this
 

SB-728-T (formerly CCR5-ZFN)

Also known as: ZFP Therapeutic for HIV/AIDS

  Manage Alerts
Collapse Summary General Information
Company Sangamo BioSciences Inc.
DescriptionAutologous CD4+ T cells genetically modified at the CC chemokine receptor 5 (CCR5) gene by CCR5-specific zinc finger DNA binding protein nucleases (ZFN)
Molecular Target CC chemokine receptor 5 (CCR5) (CD195)
Mechanism of Action 
Therapeutic ModalityGene therapy
Latest Stage of DevelopmentPhase I/II
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV infection; Treat HIV infection in treatment-naïve patients; Treat HIV/AIDS
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today